Millions Lose Coverage for Obesity Drugs as Research Explores New Hormone Treatments

In Brief

Changes in drug coverage and emerging research may affect future obesity treatment options and patient access.

Key Facts

• Twelve million people lost coverage for Zepbound and the same number for Wegovy, according to GoodRx analysis.
• Body acceptance advocate Katie Sturino discussed her decision to start GLP-1 weight loss drugs and the challenges involved.
• Oklahoma researchers found the hormone FGF21 targets the same brain region as GLP-1 drugs but increases metabolic rate instead of reducing appetite.
• Psychiatrist Dr. Sue Varma emphasized the importance of medical consultation before starting GLP-1 drugs and discussed societal pressures.
• Scientists say FGF21 may offer an alternative approach to obesity treatment by affecting metabolism.

What Happened

Millions have lost insurance coverage for popular obesity drugs Zepbound and Wegovy, while researchers are investigating FGF21, a hormone that may offer a new treatment pathway. Patients and advocates are weighing the medical and social implications of these developments.

Why It Matters

Loss of coverage for established obesity drugs may limit patient access, while new scientific findings could shape future therapies. The evolving landscape highlights both medical and societal considerations in obesity treatment.

What's Next

Further research on FGF21's effectiveness and safety is expected, and policy changes may influence drug coverage. Patients and providers will continue to navigate treatment decisions amid shifting options.